Activity
Mon
Wed
Fri
Sun
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
What is this?
Less
More

Memberships

Cancer Warriors

484 members • Free

15 contributions to Cancer Warriors
Great lecture by Dr Duraj
Hi all, this is a great lecture by the highly intelligent and humble Dr Tomas Duraj - a research partner of Prof. Seyfried who kindly wrote the foreword for my book. Obviously Prof. Seyfried is the GOAT, but I find Dr Duraj’s presentations about metabolic therapy and in particular his explanation of OXPHOS and AMPK much easier to digest.
1 like • 16h
This is so good!
Carnitine
Merry christmas everyone! I'm just listening to the latest podcast with Dr Casey Peavler and Tomas Duraj and they mention adding in carnitine to aid with ketosis. Has anyone tried this or have any experience with carnitine? https://youtu.be/DnKKsXBIxOY?si=Ugdze4WngJFxMyPo
0 likes • 2d
@Egg Scrambled it's for my dad and his ketones are usually 1-2 with glucose 4-6. So GKI usually 3-6. Although this morning his ketones were 3 and GKI 1.7! We're struggling with maintaining his weight mostly due to poor appetite so he doesnt want to do any fasting, apart from intermittent fasting.
John Hopkins New Mebendazole Patient
https://www.facebook.com/share/p/1CU1QfHe5u/ Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research: Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties. Background: Why Mebendazole Matters Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated: Microtubule inhibition in cancer cells Disruption of glucose metabolism in malignant tissues Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2) Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable. What Johns Hopkins Has Patented The new patent centers on: Polymorph C — a redesigned crystalline form This form appears to demonstrate: Improved oral absorption Higher plasma concentrations Prolonged systemic exposure Greater potency in killing cancer cells in vitro compared with existing polymorphs This is scientifically notable, because mebendazole traditionally suffers from: Poor gastrointestinal absorption High inter-individual variability Low bioavailability unless taken with high-fat meals A more bioavailable crystalline form directly addresses these limitations. Synergy Through Transporter Inhibition The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of: P-glycoprotein (P-gp) Breast Cancer Resistance Protein (BCRP) These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.
0 likes • Nov '25
@Christine Michaud can i ask where did you get it from?
1 like • Nov '25
@Christine Michaud thank you! Was that for Mebendazole?
Radiation experience
Hey guys, I was hoping to hear how people's experience with radiation has been. My dad has stage 3 lung cancer, diagnosed in July 2025. He has had one round of chemotherapy (carboplatin) and immunotherapy (pembrolizumab) but unfortunately had a severe reaction with deranged liver function. He's been on prednisolone and mycophenolate since September to manage the liver issues, which have now thankfully normalised, he's on a weaning steroid dose now. He has been on a ketogenic diet with ivermectin since August and was on fenbendazole when his liver went off. We have stopped the fenben in case it was contributing. No more chemo for now because of the immunosuppression. He had a repeat CT scan this week which shows stable known lymph node and primary, with 2 new non-descript ground glass nodules inthe lung near his kn own primary. Unclear significance at this stage. They are now suggesting a few weeks of radiation to the lymph nodes in his chest. We are cautious of the radiation given the extreme side effect of the other conventional treatments which have affected our ability to really give metabolic therapy a proper go. Does anyone have any thoughts or experience they could share? Thanks
1 like • Nov '25
@Jeff Boldrick thanks very much for sharing your experience. I'll keep researching
1 like • Nov '25
@Lisa Drake yeah have ordered rgcc testing, just waiting for results. Hopefully we get some helpful information!
Is anyone taking Ivermectin and getting blurred vision with halos?
I just started taking Ivermectin. The dosage is 40 mg and I weigh 46 kg. I. Looking online most recommended 150 mcg/kg of weight which would be 6.9 mg (6% of what I am taking,) of ivermectin for my body weight. I am wondering if I should stop taking the medicine or if I should reduce the dosage as one serious side effect is blindness. On the other hand I have only taken it for 2 days (both days had symptoms) and maybe my body could just be getting use to the medicine Thanks for any suggestions you may have!
0 likes • Nov '25
@Seleste Skinner just reading your comment here about liver function. Sorry to hear you had that issue, my dad did too. Did your liver enzymes normalise? What do you think caused it?
1-10 of 15
Maggie Maggie
3
8points to level up
@maggie-forbes-6700
Hi there, I'm from Melbourne trying to learn as much as possible about metabolic therapy after my dad was diagnosed with lung cancer.

Active 2h ago
Joined Sep 21, 2025
Powered by